Volume 45, Issue 6 (November 2000)
Screening of Amphetamine/Methamphetamine and Their Derivatives in Urine Using FPIA and Triage™8 and the Scope and Limits of a Subsequent Identification by Means of the REMEDi™ HS System
This study describes screening and identifying amphetamines, methamphetamines, and their derivatives in urine using immunochemical (Triage™8, FPIA) and chromatographic techniques (REMEDi™ HS). Amphetamines, methamphetamines, MDMA (3,4-methylenedioxymethamphetamine), MDA (3,4-methylenedioxyamphetamine), MDE (3,4-methylenedioxyethylamphetamine), MBDB (N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine), BDB (3,4-(methylenedioxyphenyl)-2-butanamine), PMA (4-methoxyamphetamine), DOM (2,5-dimethyloxy-4-methylamphetamine), DOB (4-bormo-2,5-dimethyloxyamphetamine), amphetaminil, pholedrine, fenfluramine, and amfepramone were subjected to a comparative study. For this, the substances were analyzed to determine their specific threshold concentration for a positive detection in the Triage test and their limit of detection and positive threshold concentration for the FPIA test and the results compared.
Furthermore, the capabilities of a more detailed analysis with the REMEDi system were studied. This HPLC system was able to produce information on the single drugs and main metabolites found in the sample with the danger of false-positive or false-negative screening results greatly minimized.